Atezolizumab

Evidence Level: L5

Predicted Indications: 6

Atezolizumab

Pharmacist Assessment Report

Atezolizumab: From Transitional Cell Carcinoma to Uterine Ligament Adenocarcinoma

One-Sentence Summary

Atezolizumab is an injectable antibody-based cancer immunotherapy. The TxGNN model predicts it may be effective for uterine ligament adenocarcinoma, but no clinical trials and no publications currently support this specific prediction. It is a computational signal only.

Quick Overview

Item	Content
Original Indication	Transitional cell carcinoma (relation recorded in the knowledge graph; the local licence records give no indication text)
Predicted New Indication	Uterine ligament adenocarcinoma
TxGNN Prediction Score	0.9993
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data
Number of Listed Products	2 (valid: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Atezolizumab is generally known as an antibody that blocks PD-L1, which may restore T-cell activity against tumour cells. A plausible rationale is that gynaecological adenocarcinomas can express PD-L1 and may respond to this approach.

Nothing in the compiled data confirms this for uterine ligament adenocarcinoma. The score (0.9993) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The high score should not be read as clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered for uterine ligament adenocarcinoma.

Literature Evidence

Currently no related literature available for uterine ligament adenocarcinoma.

Closest Supported Alternative: Endocervical Carcinoma

The second-ranked prediction, endocervical carcinoma (score 0.9992), is the only prediction in this candidate with registered trials. These are early-phase studies, and no results were provided in the data.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02921269	Phase 2	Completed	11	Atezolizumab plus bevacizumab in recurrent, persistent or metastatic cervical cancer. The sample is very small and no results were provided.
NCT03738228	Phase 1	Completed	40	Atezolizumab as an immune primer and with extended-field chemoradiotherapy in node-positive locally advanced cervical cancer. It gives feasibility and safety signals only.

PMID	Year	Type	Journal	Key Findings
37467967	2023	Review	Biomedical Journal	Small cell neuroendocrine carcinoma of the cervix. It notes limited data, mostly case series, and discusses emerging therapies. It is not specific to atezolizumab.

The other predictions (adenoid cystic carcinoma of the cervix uteri, uterine ligament serous adenocarcinoma, and signet ring cell and intestinal variants of cervical mucinous adenocarcinoma) have no trials or literature in the compiled data.

India Market Information

Authorization Number	Product Name	Dosage Form	Manufacturer
219483	Tecentriq Injection	Vial of 14 ml injection	Roche Products India Pvt Ltd
217022	Tecentriq 1200mg Injection	Vial of 20 ml solution for infusion	Roche Products India Pvt Ltd

Both licences are valid single-ingredient products. The licence records contain no approved-indication text, so the approved uses cannot be confirmed from the compiled data.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Immunotherapy (PD-L1 checkpoint inhibitor), not a conventional cytotoxic agent
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Drug Interactions: The interaction screen returned 75 interactions in total. The first 20 reviewed include:
- Major: adalimumab, baricitinib, and live BCG vaccine (Tice substrain).
- Moderate: corticosteroids (hydrocortisone, prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone, budesonide, triamcinolone, deflazacort), roflumilast, azathioprine, alemtuzumab, anakinra, alefacept, and several vaccines (tetanus toxoid, anthrax, adenovirus type 4).
- Most of these involve immunosuppressants or live or inactivated vaccines, so combination use needs review.

Please refer to the package insert for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: There are no trials or publications for uterine ligament adenocarcinoma, so the evidence level is L5 and the prediction rests on the model score alone. Endocervical carcinoma is the better-supported direction, but its evidence is limited to one small Phase 2 trial (n=11) and one Phase 1 trial.

To proceed, the following is needed:

Mechanism of action data and PD-L1 expression data for uterine ligament adenocarcinoma
Trial results or published outcomes for the cervical cancer studies (NCT02921269, NCT03738228)
Package insert warnings and contraindications for the Indian products, and the approved indication text
A decision on whether to prioritise endocervical carcinoma over the top-ranked prediction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.